Literature DB >> 7027040

Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study.

E G Lowrie, N M Laird, T F Parker, J A Sargent.   

Abstract

This report summarizes morbidity in 151 patients in a cooperative trial designed to evaluate the clinical effects of different dialysis prescriptions. Four treatment groups were divided along two dimensions: dialysis treatment time (long or short), and blood urea nitrogen (BUN) concentration averaged with respect to time (TACurea) (high or low). Dietary protein was not restricted. There was no difference in mortality between the groups. Withdrawal of patients from the high-BUN groups for medical reasons was significantly greater than withdrawal from the low-BUN groups. Hospitalization was also greater in the high-BUN groups, but dialysis treatment time had no significant effects. The data indicate that the occurrence of morbid events is affected by the dialysis prescription. Increased morbidity appears to accompany prescriptions associated with a relatively high BUN. Conversely, morbidity may be decreased by prescriptions associated with more efficient removal of urea if the dietary intake of protein and other nutrients is adequate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7027040     DOI: 10.1056/NEJM198111123052003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  82 in total

Review 1.  The clinical trial imperative.

Authors:  Debbie Gipson; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

2.  In-center hemodialysis six times per week versus three times per week.

Authors:  Glenn M Chertow; Nathan W Levin; Gerald J Beck; Thomas A Depner; Paul W Eggers; Jennifer J Gassman; Irina Gorodetskaya; Tom Greene; Sam James; Brett Larive; Robert M Lindsay; Ravindra L Mehta; Brent Miller; Daniel B Ornt; Sanjay Rajagopalan; Anjay Rastogi; Michael V Rocco; Brigitte Schiller; Olga Sergeyeva; Gerald Schulman; George O Ting; Mark L Unruh; Robert A Star; Alan S Kliger
Journal:  N Engl J Med       Date:  2010-11-20       Impact factor: 91.245

Review 3.  Hypertension in Pediatric Dialysis Patients: Etiology, Evaluation, and Management.

Authors:  Raj Munshi; Joseph T Flynn
Journal:  Curr Hypertens Rep       Date:  2018-06-08       Impact factor: 5.369

Review 4.  Clinical practice guidelines for pediatric peritoneal dialysis.

Authors:  Colin T White; Manjula Gowrishankar; Janusz Feber; Verna Yiu
Journal:  Pediatr Nephrol       Date:  2006-07-04       Impact factor: 3.714

Review 5.  Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose.

Authors:  John T Daugirdas
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

6.  Urea percentiles in children with chronic renal failure. Data from the ItalKid project.

Authors:  Giovanni Montini; Lorena Pisanello; Sara Testa; Valeria Daccò; Luca Dello Strologo; Emanuela Taioli; Graziella Zacchello; Luigi Avolio; Antonio Ciofani; Aldo Claris-Appiani; Gianluigi Ardissino
Journal:  Pediatr Nephrol       Date:  2003-02-27       Impact factor: 3.714

7.  Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis.

Authors:  Sheldon C Leong; Justin N Sao; Abigail Taussig; Natalie S Plummer; Timothy W Meyer; Tammy L Sirich
Journal:  J Am Soc Nephrol       Date:  2018-05-04       Impact factor: 10.121

Review 8.  Approaches to uremia.

Authors:  Timothy W Meyer; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

Review 9.  Can twice weekly hemodialysis expand patient access under resource constraints?

Authors:  Dipal Savla; Glenn M Chertow; Timothy Meyer; Shuchi Anand
Journal:  Hemodial Int       Date:  2016-12-14       Impact factor: 1.812

10.  What Is Known and Unknown About Twice-Weekly Hemodialysis.

Authors:  Yoshitsugu Obi; Rieko Eriguchi; Shuo-Ming Ou; Connie M Rhee; Kamyar Kalantar-Zadeh
Journal:  Blood Purif       Date:  2015-11-17       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.